Sopharma’s Board of Directors filed a GSM invitation for 15 January 2027, where shareholders would vote on new buyback procedure under the following conditions: not more than 3% of the capital per calendar year at a minimum price per share of EUR 0.51 and a maximum price per share of EUR 4.00 with 3 years term of the procedure. Note that currently Sopharma does not have any treasury stock.